PP178 - ASSESSMENT OF VISCERAL ADIPOSITY BY NUTRITIONAL ULTRASOUND IN OVERWEIGHT AND OBESE PATIENTS TREATED WITH SEMAGLUTIDE 2.4 MG

PP178

ASSESSMENT OF VISCERAL ADIPOSITY BY NUTRITIONAL ULTRASOUND IN OVERWEIGHT AND OBESE PATIENTS TREATED WITH SEMAGLUTIDE 2.4 MG

M. García Olivares^1,*, L. Dalla Rovere¹, R. Fernandez Jimenez¹, C. M. Hardy Añon¹, C. Herola Cobos¹, J. M. Garcia Almeida¹

¹Endocrinology and Nutrition, QuirónSalud Hospital, Malaga, Spain

Rationale: Visceral adiposity is a major cardiometabolic risk factor, in patients with obesity. Nutritional ultrasound allows direct assessment of regional fat distribution, complementing other body composition techniques such as BIA.
Our aim is to evaluate the impact of treatment with semaglutide 2.4 mg on visceral and subcutaneous fat assessed by nutritional ultrasound.

Methods: A prospective observational study was conducted in 84 patients with obesity. Morphofunctional assessment was performed at baseline and after 3 months. Ultrasound measurements included visceral adipose tissue (VAT), subcutaneous adipose tissue (T-SAT), leg subcutaneous adipose tissue (L-SAT). FM was assessed by vector bioelectrical impedance analysis (Akern). Pearson correlation analyses, and linear regression models were applied.

Results: After 3 months of treatment (semaglutide 2.4mg), a significant reduction was observed in all ultrasound fat compartments. VAT decreased by 1.34 cm (p<0.001), abdominal SAT by 1.71 cm (p<0.001), leg SAT by 0.30 cm (p<0.001). %FM measured by BIA decreased by 2.54% (p<0.001).

Significant correlations were observed between %FM and ultrasound, being strongest for L-SAT (r=0.72; p<0.001), abdominal SAT (r=0.63; p=0.005) and VAT (r=0.49; p=0.013). Linear regression analysis showed that %FM was significantly associated with weight (β=0.17; p<0.001), female sex (β=−8.53; p<0.001), L-SAT thickness (β=3.69; p<0.001), with an R² of 0.709.

Conclusion: Nutritional ultrasound is a sensitive tool for detecting changes in fat distribution, particularly visceral and subcutaneous compartments, following treatment with semaglutide. Its ability to identify predictors of excess adiposity support its clinical value for monitoring patients with obesity in routine clinical practice.

Disclosure of Interest: None declared